Latest news for Orexo (OTC:ORXOY) Stock

Orexo AB has operations in Sweden and the United States. Operations are monitored and presented in the segments USA Pharma, Digital Therapeutics (DTx), and HQ & Pipeline. The majority is from the USA Pharma segment. Geographically, the majority is derived from the United States. USA Pharma includes the commercialization of fully owned pharmaceuticals in the United States market. Digital Therapeutics include the commercialization of Orexo's groundbreaking evidence-based digital therapeutics, mainly in the United States market, which is in an early development stage. HQ &Pipeline includes the Development of pharmaceuticals performed at Orexo's headquarters in Uppsala, Sweden.

Biotech

News

Penny Stocks

Health Care

General

INVVY

IZQVF

ORXOF

ORXOY

The FDA warned patients and prescribers about the risk of potential dental problems arising from the us

Using Opioid Addiction Drug Buprenorphine May Cause Dental Issues, FDA Flags

Movers & Shakers

Small Cap

Events

Global

Markets

Trading Ideas

ETFs

BNIGF

EMMA

LXRP

MBRX

NRIFF

RDHL

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.

In addition to causing chaos in markets and economies around the world, the spread of the COVID-19 coronavirus has put the biotechnology and health care industries under the microscope.

With The World In The Midst Of A Pandemic, Attention Turns To Life Sciences

Orexo AB

Reported Earlier, Walker & Dunlop Arranges $167M Sale Of Millennium PQ, Second Largest Single-Asset Sale In California For 2024

TRIN

Reported Earlier, Trinity Capital Prices Underwritten Public Offering Of $100M 7.875% Notes Due 2029

Reported Earlier, ImmunoPrecise Secures Up To $3M Financing Agreement With Yorkville Advisors Global, LP For Convertible Debentures

ASML Holding NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>), the leading supplier of equipment to computer chip manufacturers, has <a href="https://www.benzinga.com/markets/equities/24/07/39786895/asml-expected-to-beat-estimates-with-over-5b-in-orders-during-q2-thanks-to-rising-ai-chip-demand">exceeded second-quarter earnings forecasts</a>, driven by robust sales in China and a surge in new bookings.
What Happened: The Dutch company <a href="https://www.asml.com/en/news/press-releases/2024/q2-2024-financial-results-80ef70c80ffb6d2a">reported</a> a second-quarter net income of 1.6 billion euros ($1.75 billion) on revenues of 6.2 billion euros ($6.77 billion), surpassing analysts&#8217; expectations of 1.41 billion euros on revenue of 6.04 billion euros, Reuters reported on Wednesday. 
The new bookings for the quarter stood at 5.6 billion euros ($6.11 billion), a significant increase from the 3.6 billion euros in the first quarter of 2024.
Christophe Fouquet, the new CEO, described 2024 as a &#8220;transition year,&#8221; with the company&#8217;s performance expected to remain flat as it gears up for a strong 2025. He attributed the industry&#8217;s recovery and growth to significant advancements in AI.
Despite the impressive figures, the second-quarter numbers were lower than the same period in the previous year, when net income was 1.94 billion euros and sales were 6.90 billion euros.
Analysts had <a href="https://www.benzinga.com/markets/equities/24/07/39786895/asml-expected-to-beat-estimates-with-over-5b-in-orders-during-q2-thanks-to-rising-ai-chip-demand">anticipated ASML to exceed estimates</a> with over 5 billion euros in orders during second quarter, thanks to the escalating demand for AI chips, as noted by Kevin Wang, an analyst at Mihuzo.
The surge in new orders is primarily fueled by strong demand from leading chip manufacturers, including Taiwan Semiconductor Mfg. Co. Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>), which produces chips for NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>).
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39764702/bitcoin-ethereum-dogecoin-recover-as-market-reacts-positively-to-trump-escaping-assassinat?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Bitcoin, Ethereum, Dogecoin Recover As Market Reacts Positively To Trump Escaping Assassination Attempt: : Analyst Predicts King Crypto&#8217;s Pullback Before Rise To $63.8K</a>
Why It Matters: The strong performance comes amid escalating tensions in the U.S.-China chip war. The Eindhoven University of Technology, a <a href="https://www.benzinga.com/news/24/07/39793205/asml-backed-university-finds-itself-caught-in-the-middle-of-us-china-chips-war">significant talent source</a> for ASML, has come under increasing scrutiny from the U.S. due to its large number of Chinese students.
Earlier this year, under U.S. pressure, the Dutch government imposed restrictions on exports of ASML's immersion DUV lithography machines to China. Despite these restrictions, ASML has managed to secure substantial orders, driven by the rising demand for AI chips. 
Additionally, the U.S. has been pressuring its allies, including Japan and the Netherlands, to tighten export controls on chipmaking equipment to China. This move is part of a broader strategy to <a href="https://www.benzinga.com/markets/equities/24/06/39396293/us-pressures-japan-and-netherlands-to-tighten-chip-equipment-exports-to-china-report">prevent China from acquiring advanced semiconductor technology</a> that could enhance its military capabilities.
Price Action: ASML stock closed at $1,068.19, up 0.43% on Tuesday. In after-hours trading, the stock rose by an additional 0.27%. Year to date, ASML&#8217;s stock has increased by 49.00%, according to <a href="https://pro.benzinga.com/dashboard">data from Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/07/39770159/why-tesla-shares-are-shooting-up-in-premarket?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Why Tesla Shares Are Shooting Up In Premarket</a></li>
</ul>
Image Via Shutterstock
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Kaustubh-Bagalkote" target="_blank" rel="noreferrer noopener">Kaustubh Bagalkote</a>

Earnings

Earnings Beats

Equities

Tech

AAPL

ASML

NVDA

ASML Beats Q2 Earnings Expectations With Strong China Sales, AI Chip Demand

Macro Economic Events

Econ #s

Economics

U.K. Consumer Prices Index Including Owner Occupiers' Housing Costs (YoY) 2.8% Vs. 2.8% Prior

USI is delighted to announce the official opening of its new Tonala Site in a grand ceremony on&nbsp;July 16th. The ceremony was attended by prominent guests, including&nbsp;Roberto Arechederra&nbsp;as&nbsp;Jalisco&nbsp;Governor&#39;s Rep and Economic Minister of the state,&nbsp;Sergio Chavez Mayor&nbsp;of Tonala Municipality; Alfonso Olvera Economic minister of Tonal&aacute; and&nbsp;Guillermo del Rio, Index Chamber President

Reported Earlier, ASE Technology's USI Expands Global Footprint With Completion Of Tonala Site In Mexico

Expands the company&#39;s lineup of greenhouse gas-free products, helping to achieve carbon neutrality

MIELY

Reported Earlier, Mitsubishi Electric Secures Order For 84kv Dry Air Insulated Switchgear From Kansai Transmission, Advancing Carbon Neutrality

U.K. Producer Price Index (PPI) Input (MoM) For June -0.8% Vs. 0.1% Est.; -0.6% Prior

U.K. Consumer Price Index (YoY) For June 2.0% Vs. 1.9% Est.; 2.0% Prior

U.K. Consumer Price Index (MoM) For June 0.1% Vs. 0.1% Est.; 0.3% Prior

OSIS

Reported Earlier, OSI Systems Prices Upsized $300M 2.25% Convertible Senior Notes Due 2029, Increased from Initial $275M Offering

For the quarter ended 30 June 2024, BW Product Services reported an estimated gross profit of approximately USD 26 million. Gross profit represents the realised trading profit plus net derivative gains and losses from open cargo contracts and hedging transactions.

BWLP

BW LPG Reports $26M Gross Profit For Q2 2024 In Product Services Segment Performance Update

<ul>
<li>After four weeks of treatment, CT-996 demonstrated clinically meaningful weight loss of&nbsp;-7.3%&nbsp;(weight loss in placebo&nbsp;-1.2%; p &lt; 0.001)1&nbsp;&ndash;</li>
<li>Pharmacokinetic data supports a once-daily oral dosing regimen for CT-9961&nbsp;&ndash;</li>
<li>The safety and tolerability profile was consistent with other oral GLP-1 receptor agonists and no unexpected safety signals were observed1&nbsp;&ndash;</li>
</ul>

RHHBF

RHHBY

RHHVF

Roche's Genentech Reveals Phase I Results Of Its Oral GLP-1 Receptor Agonist CT-996 For The Treatment Of People With Obesity

Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) has started taking questions from shareholders to address during the company&#8217;s second-quarter earnings call.
What Happened: Tesla&#8217;s second-quarter earnings call is scheduled for July 23, 5:30 pm ET. Shareholders have already started pouring in questions, which may likely be answered by the company&#8217;s <a href="https://www.benzinga.com/news/24/06/39305704/tesla-investor-relations-chief-martin-viecha-to-depart-after-annual-shareholder-meeting-elon-musk-sa">new investor relations hea</a>d Travis Axelrod.
A whopping number of questions raised by shareholders are centered around the company&#8217;s stainless steel Cybertruck. The questions range from possible timelines for the release of the vehicle outside the U.S., a timeline for the availability of Tesla&#8217;s driver assistance technology called Full Self Driving or FSD on the vehicle, and even details on its production rate.
Other popular topics among shareholders as of now seem to be FSD and robotaxi. Shareholders raised queries on possible FSD transfer offers, price drops, and timelines for the technology&#8217;s availability in Europe and China, among others. 
As for the robotaxi, the key question is when the product will be unveiled. Though Tesla CEO Elon Musk initially pegged the robotaxi event for Aug. 8, he <a href="https://www.benzinga.com/news/24/07/39785823/elon-musk-confirms-delay-in-tesla-robotaxi-unveil-due-to-important-design-change-but-stays-mum-on-ne">recently confirmed media reports</a> and said on X that he has requested a few design changes to the vehicle, thereby delaying the event. 
Shareholders have until June 23, 4 pm ET to submit questions, meaning a lot more questions are potentially on the way.
Why It Matters: Tesla delivered 443,956 vehicles <a href="https://www.benzinga.com/markets/equities/24/07/39595720/tesla-deliveries-fall-for-second-straight-quarter-but-stock-takes-off-as-q2-numbers-exceed-expec">in the second quarter</a> globally, marking a 4.8% drop from last year but still beating the consensus estimate. The company also deployed 9.4 GWh of energy storage products in the quarter, marking the highest quarterly deployment to date. 
The financial results for the second quarter are now scheduled for after the market closes on July 23. 
In the second quarter of 2023, Tesla reported total revenue of $24.93 billion and adjusted EBITDA of $4.65 billion after delivering 466,140 vehicles.
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link</a>.
Read More:
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39789388/teamsters-union-considers-withholding-endorsement-for-both-trump-and-biden-after-supporting-democrat">Teamsters Union Considers Withholding Endorsement For Both Trump And Biden After Supporting Democrats For Decades: Report</a></li>
</ul>

TSLA

Cybertruck Curiosity Grips Tesla Shareholders As Elon Musk-Led EV Giant Starts Taking Questions For Upcoming Earnings Call

Birks Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BGI#AMEX">BGI</a>) reported quarterly losses of C$(0.24) per share. This is a 40 percent increase over losses of C$(0.40) per share from the same period last year. The company reported C$185.28 million in sales this quarter. This is a 13.70 percent increase over sales of C$162.95 million the same period last year.

Birks Group FY EPS C$(0.24) Up From C$(0.40) YoY, Sales C$185.28M Up From C$162.95M YoY

Australian computer scientist Craig Wright, who has consistently claimed to be the creator of Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), has been ordered by a judge in the United Kingdom to publicly deny being Satoshi Nakamoto, the pseudonymous founder of the world&#8217;s largest cryptocurrency.
What Happened: In an order issued Tuesday, James Mellor directed Wright to announce on his website, Slack, and X that he is not the founder of Bitcoin, as per a <a href="https://www.theblock.co/post/305731/craig-wright-forced-to-post-that-he-is-not-actually-bitcoin-founder-satoshi-nakamoto-following-uk-ruling?utm_source=twitter&amp;utm_medium=social">report </a>by The Block.
Judge Mellor stated, &#8220;I do not consider a notice on his website on its own to be adequate.&#8221; He ordered the publication of an amended notice on Wright&#8217;s website homepage, X feed, and all Slack channels for a period of three to six months.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39807242/donald-trump-plans-launch-of-fourth-nft-collection-im-going-to-do-another-one-because-the-">Donald Trump Plans Launch Of Fourth NFT Collection: &#8216;I&#8217;m Going To Do Another One Because The People Want Me To Do Another One&#8217;</a>
Wright&#8217;s website now reflects these <a href="https://craigwright.net/">changes,</a> with a legal disclaimer denying his claims of being Nakamoto, and his copyright ownership of the Bitcoin whitepaper.
Why It Matters: This development follows a series of legal battles involving Wright&#8217;s claims to be the creator of Bitcoin. In February, <a href="https://www.benzinga.com/markets/cryptocurrency/24/02/36949178/is-craig-wright-actually-satoshi-nakamoto-bitcoins-alleged-creators-assertion-deemed-a-bra">Wright&#8217;s assertion was deemed a &#8216;brazen lie&#8217;</a> in a U.K. High Court. The Crypto Open Patent Alliance, backed by Twitter founder Jack Dorsey, sought a &#8220;negative declaration&#8221; that Wright is not Nakamoto.
In March, Judge Mellor ruled that Wright is not Satoshi Nakamoto or the author of the Bitcoin whitepaper, concluding weeks of legal proceedings. Wright first claimed to be Satoshi in 2016.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I think you should have a read of my whitepaper again. Nodes create blocks. Try understanding what that means. <a href="https://t.co/Olmcfv9Vhp">pic.twitter.com/Olmcfv9Vhp</a>
&mdash; Dr Craig S Wright (@Dr_CSWright) <a href="https://twitter.com/Dr_CSWright/status/1613866418218618880?ref_src=twsrc%5Etfw">January 13, 2023</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The real identity of Satoshi Nakamoto, who arguably enjoys a cult status in the cryptocurrency space, continues to be a mystery.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39807951/why-are-gamestop-and-kitty-themed-memecoins-trading-higher-today-read-on">Why Are GameStop And Kitty-Themed Memecoins Trading Higher Today? Read On</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.<a href="https://benzinga.com/apis" rel="noreferrer noopener" target="_blank"></a>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Craig Wright Adds Disclaimer To Website Admitting He's Not Bitcoin-Founder Satoshi Nakamoto

&quot;We expect third-quarter total net sales between &euro;6.7 billion and &euro;7.3 billion with a gross margin between 50% and 51%. ASML expects R&amp;D costs of around &euro;1,100 million and SG&amp;A costs of around &euro;295 million. Our outlook for the full year 2024 remains unchanged. We see 2024 as a transition year with continued investments in both capacity ramp and technology. We currently see strong developments in AI, driving most of the industry recovery and growth, ahead of other market segments,&quot; said ASML President and Chief Executive Officer Christophe Fouquet. &nbsp;

Guidance

ASML Expects Q3 2024 Net Sales Of €6.7B-€7.3B Vs. €7.608B Consensus; Sees Gross Margin Between 50%-51%

ASML's Q2 Net Bookings Totaled €5.667B Of Which €2.5 Billion Is EUV

ASML Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) reported quarterly earnings of €4.01 per share which beat the analyst consensus estimate of €3.71 by 8.09 percent. This is a 18.66 percent decrease over earnings of €4.93 per share from the same period last year. The company reported quarterly sales of €6.242 billion which beat the analyst consensus estimate of €6.032 billion by 3.49 percent. This is a 9.56 percent decrease over sales of €6.902 billion the same period last year.

ASML Holding Q2 2024 GAAP EPS €4.01 Beats €3.71 Estimate, Sales €6.242B Beat €6.032B Estimate

Cryptocurrencies linked to legendary trader &#8220;Roaring Kitty" surged higher Tuesday on high short interest in meme stock, GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>).
What Happened: GameStop (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">GME</a>), the Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)-based meme coin that pays tribute to the historic 2021 short squeeze, jumped 10% in the last 24 hours.&nbsp;
Additionally, Kitty AI (CRYPTO: KITTY) shot up 25%, with a 10% jump in 24-hour trading volumes.&nbsp;
Both of these memecoins have no fundamental ties to GameStop or Roaring Kitty but are just playing on <a href="https://www.benzinga.com/news/24/07/39799183/whats-going-on-with-gamestop-stock">the speculations of a short squeeze of the meme stock </a>and a possible repetition of the 2021 event.
See Also:<a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39359780/dogecoin-shiba-inu-floki-are-dino-coins-says-trader-he-likes-these-3-other-meme-coins-as-b?itm_source=parsely-api"> </a><a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39785549/pepe-dogwifhat-floki-explode-amid-searing-memecoin-rally-dogecoin-shiba-inu-rise-as-well">Pepe, dogwifhat, Floki Explode Amid Searing Memecoin Rally — Dogecoin, Shiba Inu Rise As Well</a>
Why It Matters: Keith Gill, better known online as &#8220;Roaring Kitty,&#8221;<a href="https://www.benzinga.com/markets/equities/24/06/39128364/roaring-kitty-just-posted-a-reverse-uno-card-what-does-it-signal-for-gamestop-amc-shares"> </a>has <a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39128955/roaring-kittys-new-social-post-pushes-gamestop-themed-crypto-by-200-kitty-themed-coins-sur">set the stock and cryptocurrency markets on fire with his social media comeback in May. </a>
The trader has posted position updates on Reddit and <a href="https://www.benzinga.com/markets/equities/24/06/39231962/roaring-kitty-draws-600k-live-viewers-in-youtube-return-im-alive">even held a livestream during market hours </a>on his YouTube channel.
His sporadic posts continue to inject volatility into GameStop and Kitty-themed memecoins.  
Price Action: At the time of writing, GME was exchanging hands at $0.00661, up 10.84% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA..">data from Benzinga Pro</a>. Shares of GameStop closed 5.85% higher at $28.58 during Tuesday's regular trading hours.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39801438/is-hester-peirce-the-next-sec-boss-potential-gensler-successor-urges-crypto-cooperation-wi">Is Hester Peirce The Next SEC Boss? Potential Gensler Successor Urges Crypto Cooperation With CFTC: &#8216;We Both Serve The American People</a>&#8216;</li>
</ul>

Movers

$GME

$SOL

Why Are GameStop And Kitty-Themed Memecoins Trading Higher Today? Read On

Orexo AB GAAP EPS of -SEK 0.37, revenue of SEK 157.7M

Orexo AB reports Q3 interim results

Orexo AB GAAP EPS of -SEK0.54, revenue of SEK166M

Orexo AB reports Q1 results

Press Releases

Orexo publishes the Annual and Sustainability Report for 2023

Orexo announces that the condition for early redemption of its existing bonds has been fulfilled

Orexo extends patent protection for its nasal epinephrine powder product OX640 in the US

Report from Orexo AB's annual general meeting, 26 April 2024

Orexo Q1 2024 Interim Report

Orexo publishes prospectus and applies for admission to trading of social bonds on Nasdaq Stockholm

Orexo: invitation to presentation of the Q2 2024 Interim Report

Orexo AB's sustainability work ranked among top 5% by EcoVadis

Orexo shares new information on OX124, a high-dose naloxone rescue medication in development for opioid overdose

Orexo Q2 2024 Interim Report

Orexo

The&nbsp;<a class="editor-rtfLink" href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-risks-dental-problems-associated-buprenorphine-medicines-dissolved-mouth-treat" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">FDA warned patients and prescribers</a>&nbsp;about the risk of potential dental problems arising from the use of buprenorphine medicines to treat opioid addiction and pain.

<ul>
	<li>The agency said the opioid addiction treatment had been reported to cause tooth decay, infection, and, in some cases, total tooth loss in patients with no history of dental issues.</li>
	<li>The buprenorphine medicines that are associated with dental problems are tablets dissolved under the tongue and films placed against the inside of the cheek.</li>
	<li>The FDA approved buprenorphine as a tablet in 2002 and as a film in 2015.</li>
	<li>It said patients might lessen their risk by taking preventative measures.</li>
	<li>After the product is completely dissolved, patients should take a large sip of water, swish it gently around their teeth and gums, and swallow, waiting for at least one hour before brushing their teeth after using the product to avoid damage to the teeth.</li>
	<li>The regulator&#39;s approved buprenorphine products include&nbsp;Orexo AB&#39;s&nbsp;(OTC:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/orxof#OTC" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">ORXOF</a>) Zubsolv and&nbsp;Indivior Plc&#39;s&nbsp;(OTC:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/invvy#OTC" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">INVVY</a>) Suboclade.</li>
</ul>

The following post was written and/or published as a collaboration between Benzinga&rsquo;s in-house sponsored content team and a financial partner of Benzinga.

In addition to causing chaos in markets and economies around the world, the spread of the COVID-19 coronavirus has put the biotechnology and health care industries under the microscope.

Suddenly, hundreds of such companies are redirecting resources in an effort to find a vaccine or treatment that could potentially halt the virus&rsquo; spread. This has made the biotech space one of the few hot spots in a historically bad month for stocks.

The shelter-in-place orders in the U.S. and other countries have also made it difficult for many of these companies to communicate directly with investors. This is especially challenging for biotech companies, which are often more communicative with investors than companies in other industries. Expensive drug trial and capital raising cycles, make constant communication with investors essential, according to John Viglotti, senior vice president of corporate services and investor access at OTC Markets.

&ldquo;They are faced with a constant need to raise capital to fund clinical trials, and these clinical trials are not stopping,&rdquo; he said. &ldquo;The life science business is certainly continuing.&rdquo;

In an effort to bridge that gap between investors hungry for information and companies trying to reach them, OTC Markets is hosting the first <a href="https://www.lifesciencesinvestorforum.com/events/event-details/agenda?utm_source=Article&amp;utm_medium=Benzinga&amp;utm_campaign=LSIF%2003262020">Virtual Life Science Investor Forum</a> on March 26. The online-only conference will consist of investor presentations from seven companies in five countries. Some will be giving updates on their COVID-19 treatments.

&ldquo;Certainly with what&rsquo;s going on with the coronavirus pandemic, it just makes it that much more relevant,&rdquo; said Jason Paltrowitz, executive vice president of corporate services at OTC Markets. &ldquo;The public at large is certainly interested in COVID-19, but from an investor perspective there are great opportunities.&rdquo;

According to Viglotti, over 200 life sciences companies have previously participated in virtual investor conferences, making it one of the most popular sectors to participate in the conference series.

&ldquo;It was really done with the realization that there are so many pre-revenue, early stage private life science companies that are just starved for attention,&rdquo; Paltrowitz said of this week&rsquo;s conference. &ldquo;And we thought being able to host a series of virtual conferences would help.&rdquo;

Below is the schedule for the conference. Each presentation is followed by a virtual Q&amp;A session with attendees and is available on demand.

To learn more about attending Thursday&rsquo;s conference, <a href="https://www.lifesciencesinvestorforum.com/events/event-details/agenda?utm_source=Article&amp;utm_medium=Benzinga&amp;utm_campaign=LSIF%2003262020">click here</a>.

9:30 AM ET RedHill Biopharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDHL#NASDAQ">RDHL</a>) 
Speaker: Guy Goldberg, Chief Business Officer 
About: RedHill is a specialty biopharmaceutical company focused on gastrointestinal diseases. RedHill has commercial operations in the U.S., with a sales force promoting several gastrointestinal drugs across the U.S., including RedHill&rsquo;s recently FDA approved drug, Talicia&reg;. RedHill also has a robust development pipeline with several late-stage development programs which have successfully completed Phase 3 studies.

10:00 AM ET Nuvo Pharmaceuticals Inc. (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/NRIFF#OTCQX">NRIFF</a>) 
Speakers: Jesse Ledger, President &amp; Chief Executive Officer, and Kelly Demerino, Interim Chief Financial Officer 
About: Nuvo is a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products. The Company targets several therapeutic areas, including pain, allergy and dermatology. The Company&#39;s strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets.

10:30 AM ET Orexo AB (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/ORXOY#OTCQX">ORXOY</a>) 
Speaker: Nikolaj S&oslash;rensen, President &amp; CEO 
About: Orexo develops improved pharmaceuti&shy;cals and digital therapies addressing unmet needs mainly within the growing space of addiction. The products are commercialized by Orexo in the US or via partners worldwide. The main market today is the American market for buprenorphine/naloxone products, where Orexo commercializes its lead product Zubsolv&reg; for treatment of opioid use disor&shy;der.

11:00 AM ET Emmaus Life Sciences, Inc. (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/EMMA#OTCQB">EMMA</a>) 
Speakers: Dr. Yutaka Niihara, Chairman and Chief Executive Officer, and Jay Sherwood 
Chief Financial Officer

About: Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sale of innovative treatments and therapies, including those in the rare and orphan disease categories. Its FDA-approved Endari&reg; (prescription grade L-glutamine oral powder) is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.

11:30 AM ET Moleculin Biotech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>) 
Speaker: Walter Klemp, Founder, President, CEO &amp; Chairman 
About: Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors. The Company&#39;s clinical stage drugs are: Annamycin, a Next Generation Anthracycline, designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic cancer and hematologic malignancies, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in preclinical development of additional drug candidates, including additional Immune/Transcription Modulators, as well as compounds capable of Metabolism/Glycosylation Inhibition.

12:00 PM ET Lexaria Bioscience Corp. (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/LXRP#OTCQX">LXRP</a>) 
Speaker: Chris Bunka, CEO 
About: Lexaria Bioscience Corp. is a global innovator in drug delivery platforms. Its patented DehydraTECH&trade; drug delivery technology changes the way API&#39;s enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. DehydraTECH increases bio-absorption; reduces time of onset; and can reduce drug costs for orally administered bioactive molecules including nicotine, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and other molecules. Lexaria has licensed DehydraTECH to multiple companies for use in various oral application formats, including to a world-leading tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide.

12:30 PM ET Beroni Group Ltd. (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/BNIGF#OTCQX">BNIGF</a>) 
Speakers: Jacky Zhang, Chairman and CEO, and Peter Wong, Group CFO 
About: Beroni Group is an international biotechnological company listed on the National Stock Exchange (Australia) with business presence in Australia, China, Japan and the USA. It currently has four core businesses - cell therapies, developing new anti-cancer drugs, e-commerce platform for pharmaceutical and healthcare products, and detection &amp; diagnosis of infectious diseases.

To learn more about attending Thursday&rsquo;s conference, <a href="https://www.lifesciencesinvestorforum.com/events/event-details/agenda?utm_source=Article&amp;utm_medium=Benzinga&amp;utm_campaign=LSIF%2003262020">click here</a>.

Photo by&nbsp;<a href="https://unsplash.com/@thisisengineering?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText">ThisisEngineering RAEng</a>&nbsp;on&nbsp;<a href="https://unsplash.com/s/photos/laboratory?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText">Unsplash</a>

The preceding post was written and/or published as a collaboration between Benzinga&rsquo;s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

Orexo

News

Latest news for Orexo (OTC:ORXOY) Stock

Thursday, January 13, 2022

Wednesday, March 25, 2020